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Abstract
Background The use of herbal medicinal products (HMPs)
is common among older adults; however, little is known
about concurrent use with prescription drugs, as well as
potential interactions associated with such combinations.
Objective The aim of this systematic review was to iden-
tify and evaluate the literature on concurrent prescription
and HMP use among older adults to assess prevalence,
patterns, potential interactions and factors associated with
this use.
Methods Systematic searches were conducted in the
MEDLINE, PsycINFO, EMBASE, CINAHL, AMED, Web
of Science and Cochrane databases from inception to May
2017 for studies reporting concurrent use of prescription
medicines with HMPs in adultsC 65 years of age. Quality
was assessed using the Joanna Briggs Institute checklists.
And the Evidence for Policy and Practice Information and
Co-ordinating Centre (EPPI-Centre) three-stage approach
to mixed method research was used to synthesise data.
Results Twenty-two studies were included. A definition of
HMPs or what was considered an HMP was frequently
missing. Prevalence of concurrent use by older adults
varied widely between 5.3 and 88.3%. Prescription
medicines most combined with HMPs were antihyperten-
sive drugs, b-blockers, diuretics, antihyperlipidemic
agents, anticoagulants, analgesics, antihistamines, antidia-
betics, antidepressants and statins. The HMPs most fre-
quently used were Ginkgo biloba, garlic, ginseng, St John’s
wort, Echinacea, saw palmetto, evening primrose oil and
ginger. Potential risks of bleeding due to the use of Ginkgo
biloba, garlic or ginseng with aspirin or warfarin was the
most reported herb–drug interaction. Some data suggest
being female, and having a lower household income and
less than a high-school education were associated with
concurrent use.
Conclusion The prevalence of concurrent prescription
drugs and HMP use among older adults is substantial and
potential interactions have been reported. Knowledge of
the extent and manner in which older adults combine
prescription drugs will aid healthcare professionals in
appropriately identifying and managing patients at risk.
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Key Points
Concurrent use of prescription drugs and herbal
medicinal products (HMPs) among older adults is
substantial, with prevalence varying widely between
5.3 and 88.3%.
The most commonly combined prescription
medicines were antihypertensive drugs, b-blockers,
diuretics, anticoagulants, analgesics, antidiabetics,
antidepressants and statins. And the most frequently
used HMPs were Ginkgo biloba, garlic, ginseng, St
John’s wort, Echinacea, saw palmetto, evening
primrose oil and ginger.
There is still limited knowledge of the extent and
manner in which older adults combine prescription
drugs with HMPs.
1 Introduction
The world population is ageing. According to the World
Health Organization (WHO), by 2050 the population of
people agedC 60 years will double and around 400 million
people will beC 80 years of age [1]. By 2040, nearly one in
four people (24.2%) in the UK will be aged 65 years or
older [2]. With pharmacotherapy facilitating an ageing
population [3], older populations rely on complex
polypharmacy to manage chronic health conditions [4].
Older adults are the biggest consumers of prescription and
over-the-counter (OTC) medicines [5–7], and it is also
well-recognised that self- medication [8, 9] and consump-
tion of non-prescription medicines, particularly herbal and
other dietary supplements, is widespread among older
adults [10–16]. Polypharmacy [17–19] increases the risks
of adverse drug reactions (ADRs) and interactions [20, 21].
With healthcare systems increasingly burdened with more
hospitalisations and prolonged hospital stays due to ADRs
[22], potential herb–drug interactions are major clinical
and economic concerns.
In the UK, prescriptions dispensed for those aged over
60 years accounted for 51.2% of the total net cost for all
prescriptions in 2014 [23]. In addition, up to one-quarter of
adults use herbal medicinal products (HMPs) [6, 24, 25]—
medicinal products where the active ingredients consist
exclusively of herbal substances or herbal preparations
[26]. HMPs are covered by Directive 2001/83/EC on the
Community code relating to medicinal products for human
use (‘‘Directive on human medicinal products’’) [26]. They
are mostly bought over the counter, by self-prescription,
and are generally not disclosed to healthcare practitioners
[6, 24, 25]. ADRs could occur due to interactions between
conventional drugs and HMPs, some of which may have
serious consequences [15, 27–29]. For example, St. John’s
wort (Hypericum perforatum) taken with serotonin reup-
take inhibitors increases the risk of serotonin syndrome in
older adults [27]. Despite concerns of possible harmful
interactions, little is known about the concurrent use of
these medicines by older adults.
The aim of this systematic review was to identify and
evaluate the literature on concurrent prescription and HMP
use among older adults to assess (1) prevalence, (2) pat-
terns, (3) potential interactions and other safety risks, and
(4) factors associated with this use.
2 Methods
The full review protocol has previously been published
[30]. This review was conducted according to the princi-
ples of systematic review [31] and is reported following the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [32].
2.1 Eligibility Criteria
Literature searches identified studies assessing the preva-
lence and patterns of concurrent HMPs or herbal dietary
supplements used with prescription medicines. Cross-sec-
tional studies, case reports and case series were included.
However we excluded PhD theses, editorials, commen-
taries, in vitro experiments and animal studies. Studies
assessing herbal medicine as part of a therapeutic system or
system of medicine such as traditional Chinese medicine,
Ayurveda, Kampo, Siddha, Unani and homeopathic herbal
remedies were also excluded from the review. As were
studies assessing the concurrent use of vitamins, minerals
and non-herbal dietary supplements or combination prod-
ucts containing herbal and non-herbal substances with
prescription medicines.
The WHO defined ‘elderly’ as individuals over the age
of 65 years in developed countries, and over 60 years in
developing countries. For the purpose of this review, we
have adopted the minimum age of 65 years since the
majority of studies identified from our literature searches
were conducted in developed countries. Therefore, studies
with participants aged 65 years or older, studies with a
mean participant ageC 65 years, or studies from which
data for participants agedC 65 years could be extracted
were included in this review.
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2.2 Search Methods for Identification of Studies
The following databases were searched until May 2017:
Cumulative Index to Nursing and Allied Health Literature
(CINAHL) via EBSCO, Cochrane Library, Excerpta
Medica database (EMBASE) via OVID, MEDLINE via
OVID, the Allied and Complementary Medicine Database
(AMED) via EBSCO, PsycINFO via OVID, and Web of
Science. Medical Subject Headings (MeSH) and text words
included ‘herbal medicine’, ‘prescription drugs’ and
‘aged’. The scientific names and common names of herbs
most documented for concurrent use were applied to ensure
a broad search strategy.
No restrictions were placed on language of publication,
and reference lists of all identified studies were checked for
relevant studies not identified by the electronic searches.
Lateral searches were also conducted using the related
citation function in PubMed and cited by function in
Google Scholar to capture all relevant articles. The search
strategy is available as electronic supplementary Appendix
S1.
2.3 Data Collection and Analysis
2.3.1 Selection of Studies
Retrieved references from all the databases were down-
loaded into Endnote files and then merged. All duplicate
studies were recorded before discarding. Two reviewers
(TA and BW) scanned all titles and abstracts for potential
relevance. Any article for which there was uncertainty
about relevance was retained and the full text assessed.
Using a predesigned eligibility checklist, two reviewers
(TA and BW) independently assessed full-text articles
against the eligibility criteria and recorded an eligibility
code. Studies that did not meet the inclusion criteria were
excluded and the reasons recorded. Disagreements on eli-
gibility were resolved through discussions between the two
reviewers (TA and BW), and the third reviewer (CG) was
consulted if no consensus was reached. Full texts of all
articles that met the eligibility criteria were obtained and
downloaded into Endnote.
2.3.2 Data Extraction and Management
A data extraction form was designed for the review, then
piloted and amended to ensure that all the required infor-
mation could be extracted. Data from individual studies
were extracted by the first reviewer (TA) using this form,
and validated by the second reviewer (BW). Key infor-
mation extracted included:
• Publication details: authors, year of publication, coun-
try in which the study was conducted.
• Study design: study type, recruitment and data collec-
tion method.
• Participants: demographic and socioeconomic charac-
teristics, sampling and sample size, previous medical
diagnosis, etc.
• Primary outcomes: prevalence of concurrent use, name
and number of HMPs and prescription drugs, pattern of
use, and number and types of adverse reactions or
potential interactions.
• Secondary outcomes: disclosure, satisfaction or dissat-
isfaction, and cost expended on HMPs.
• Study limitations: response bias, selection bias, repre-
sentativeness of sample, etc.
2.3.3 Quality Assessment of Included Studies
The Joanna Briggs Institute (JBI) checklists for appraising
studies reporting prevalence data [33] and for case reports
[34] were used to screen selected studies prior to inclusion
in the review. Two reviewers independently assessed each
of the included studies against the criteria on the JBI
checklist to minimise bias and establish methodological
validity. The JBI checklist for prevalence studies was the
preferred assessment tool because it can be used across
different study designs reporting prevalence. The checklist
also addresses issues of internal and external validity crit-
ical to prevalence data. Any disagreements between
reviewers were resolved through discussion.
2.3.4 Data Synthesis
We used the Evidence for Policy and Practice Information
and Co-ordinating Centre (EPPI-Centre) three-stage approach
to mixed method research to synthesise data [35]. A first
synthesis was conducted to address the prevalence, pattern of
use and patient characteristics associated with concurrent use
of HMPs and prescription medicines. The second synthesis
focused on safety issues and other factors associated with
concurrent use, i.e. disclosure, satisfaction and cost/resources.
Finally, using thematic synthesis, we identified key themes
and commonalities. Findings were summarised as a narrative
account addressing each of the review questions. A detailed
discussion of the limitations of the included studies and the
implications of our findings was also provided.
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3 Results
3.1 Results of the Search
The literature searches identified 20,837 titles and
abstracts. Initial screening of titles and abstracts identified
2199 potentially relevant articles; a total of 2106 articles
were excluded for not satisfying all the inclusion criteria.
Full texts of the remaining 93 articles were obtained to
assess for eligibility. At the end of the eligibility process,
71 articles were excluded for the following reasons: type of
intervention (e.g. non-herbal combinations, non-oral;
n = 9), age (n = 24), study type (n = 19), and no con-
comitant use (n = 19). Twenty-two studies met our
inclusion criteria and were included in this systematic
review (Fig. 1).
3.2 Study Characteristics
Table 1 is a summary of included studies, providing
information on study setting, sample characteristics,
prevalence of concurrent use, and most reported prescrip-
tion medicines and HMPs, as well as interactions or
potential interactions reported from such combinations.
All included studies were published in the English lan-
guage, except one study published in Spanish [36]. Thir-
teen of the included studies were conducted in the USA
[5, 17, 37–46, 54], two in Canada [47, 48] and two in the
UK [16, 49]. Only one study each was conducted in Ireland
[50], Norway [51], Turkey [52], Spain [36] and Jamaica
[53]. The majority of studies (n = 16) were described as
cross-sectional [5, 17, 36, 38, 40–42, 44, 45, 47–53], eight
of which identified concurrent use of prescriptions with
Records identified from database searching = 20,820
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Fig. 1 Study selection process
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other medications using semi-structured interviews
[17, 36, 38, 40, 45, 47, 52, 53]; others interviewed older
people, and then checked and recorded their medications
[5, 17, 42, 48, 50, 54]. Self-completed questionnaires were
adopted in five studies [41, 42, 44, 49, 51], with partici-
pants self-reporting on the questionnaire all the medicines
they were taking. Three studies [16, 46, 54] were secondary
analyses of data from previous research and three were
case reports [37, 39, 43] of possible interactions between
herbal dietary supplements and prescription medicines.
Only four studies have been published in the last 5 years
[36, 50–52]. Seventeen studies were published between
2000 and 2010, and one case report was published in 1999
[39].
The 22 studies included in this review had a total of
18,399 participants aged 65 years or over. The average age
of participants ranged from 63 to 78 years, and the number
of participants ranged from one (case report) to 5052. Only
in ten studies was the focus on those aged 65 years or
older, with the other studies conducted among the general
population agedC 18 years, but data for participants
agedC 65 years could be extracted.
Participants were predominantly females in 12 studies,
varying between 51% [17] and 100% [46, 55]. Male par-
ticipants were the majority in five studies [16, 41–44]. The
number of males and females in the different age categories
were not specified in four studies [38, 47, 51, 53]. One
study each was conducted among older adults in hospitals
[52] and nursing homes [36]. The remaining studies were
conducted among general populations (i.e. community-
dwelling older adults) [5, 16, 17, 37–41, 46, 47,
49–51, 53, 55], outpatients of memory clinics [42, 48],
emergency department [43] and veteran centre [44].
We ensured only studies that actually evaluated HMPs
were included by looking at the definition where provided
and the herbal medications reported. However, no consis-
tent term exists for HMPs and different terms are used in
different countries. For example, in Canada, HMPs are
referred to as natural health products (NHPs), i.e. ‘‘Sub-
stances or combination of substances consisting of mole-
cules and elements found in nature and homeopathic
preparations sold in dosage forms for the purpose of
maintaining or improving health, and treating or preventing
diseases/conditions, and includes herbal medicines, vita-
mins and minerals’’ [56; p. 2]. Both Canadian studies
included in this review [47, 48] used the term ‘natural
health products’. Only one study from the US [38] used
‘herbs/natural products’, but excluded vitamins and
minerals.
Elmer et al. [54] used the term complementary and alter-
native medicine (CAM) products, defined as ‘‘products such
as herbal (botanical) products or non-botanical dietary sup-
plements (e.g. glucosamine) excluding vitamins andT
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minerals’’. Five studies [17, 39, 42, 44, 50] used the definition
of dietary supplement according to Directive 2002/46/EC of
the European Parliament and of the Council, 2002 [26], i.e.
‘‘potentially any product intended for ingestion as a supple-
ment to regular diet, including vitamins or minerals (at any
dose level), herbal products, and nutraceuticals’’. Twelve
studies [5, 16, 37, 40, 41, 43, 46, 49, 51–53, 55] provided no
definition or an explanation of HMP. All potentially eligible
studies were therefore individually screened to ensure
they met this inclusion criterion independent of the definition
used.
3.3 Synthesis of Results
3.3.1 Prevalence of Concurrent Prescription Drugs
and Herbal Medicinal Products (HMPs) Among
Older Adults
Fifteen studies reported prevalence of concurrent use,
while no such information was provided in four articles
[16, 46, 49, 53] and three were case reports where preva-
lence cannot be calculated [37, 39, 43]. Prevalence of
concurrent use varied widely between 5.3% [47] and 88.3%
[42].
Table 1 shows the most concurrently combined pre-
scription medicines and HMPs from the included studies.
The common groups of prescription medicines concur-
rently combined with HMPs were antihypertensive drugs,
b-blockers, diuretics, antihyperlipidemic agents, anticoag-
ulants, analgesics, antihistamines, antidiabetics, antide-
pressants and statins.
The most commonly used HMPs as reported in the
included studies were Ginkgo (Ginkgo biloba), garlic (Al-
lium sativum), Ginseng (Panax ginseng), St John’s wort
(Hypericum perforatum), Echinacea (Echinacea purpurea),
saw palmetto (Serenoa repens), evening primrose oil
(Oenothera biennis) and ginger (Zingiber officinale). In
some studies, non-herbal dietary or nutritional supplements
[37, 41, 42, 47, 49, 50], vitamins and minerals
[17, 42, 44, 50] and OTC conventional medicines
[40, 48, 53, 54] were also concurrently used by participants
in addition to prescription drugs and HMPs. In one study
[42], 82.5% of participants receiving prescription medici-
nes also used at least one non-herbal dietary supplement,
while 54.5% used three or more.
3.3.2 Potential Interactions and Safety Issues
Potential interactions from reported combinations of pre-
scription drugs and HMPs were evaluated using different
methods. Some studies used a combination of two or more
of the following methods: review of possible interactions
from previously published clinical data, case reports and
textbooks [16, 41, 42, 47, 51, 54], and comprehensive
online databases such as Micromedex (https://www.
micromedexsolutions.com), Natural Medicines (https://
naturalmedicines.therapeuticresearch.com/, formerly Nat-
ural Standard) and Stockley’s Drug Interactions (http://
www.pharmpress.com/product/MC_STOCK/stockleys-
drug-interactions) [5, 40, 42, 44, 46, 50].
Due to how data were presented in two studies [49, 51],
it was not possible to extract potential interactions for
participants agedC 65 years. No evaluation of potential
interactions was done in five studies [17, 42, 45, 52, 53],
while a total of 1010 individual interactions or potential
interactions were reported in 15 studies. The potential risks
of bleeding due to the use of Ginkgo biloba, garlic or
ginseng with aspirin and warfarin were the most reported
[5, 36, 37, 41, 43, 44, 46, 48, 50, 54], or with other
antithrombotic drugs [50]. Other interactions reported
included the risk of decreased international normalised
ratio (INR) [16, 37], alterations in either blood glucose or
blood pressure [40], nausea and dizziness [39], anxiety
[16], headaches [39, 43], restlessness and irritability [16].
An important and risky mode of herb–drug interaction is
the inhibition of cytochrome P450 3A4 substrates (e.g.
atorvastatin, simvastatin, amlodipine, verapamil) by garlic,
Ginkgo biloba, Echinacea and St John’s wort [38]. For
example, St. John’s wort could reduce the blood pressure-
lowering effect of losartan, or decrease the effects of
digoxin [37].
Interactions were rated by the authors as ‘major or high
risk’, ‘moderate’ or ‘minor’. The majority of potential
interactions reported in the included studies were minor
and of unknown clinical significance or uncertain risk for
an adverse interaction [16, 54]. These interactions were
cited in the literature based only on theoretical evidence
[47]. Potential major herb–drug interactions reported were
between non-steroidal anti-inflammatory drugs (NSAIDs)
and Ginkgo biloba, resulting in an increased risk of gas-
trointestinal bleeds due to decreased platelet aggregation
[46]. Other major interactions occurred between drugs and
non-herbal supplements [50], or involved the use of non-
prescription drugs [5].
3.3.3 Concurrent Use and Associated Factors
The majority of studies included in this review did not
assess concurrent use with demographic or clinical vari-
ables. For the 11 studies that assessed demographic or
clinical factors [5, 17, 38, 45, 47, 49–54], the following can
be summarised:
3.3.3.1 Ethnicity Only one study assessed the differences
in concurrent use between different ethnic groups. African
Americans used significantly more garlic (p = 0.003),
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although no significant difference was observed in the use
of ginseng or Ginkgo biloba between African Americans
and White participants [54].
3.3.3.2 Sex and Age An important sex difference in
medication use among older adults was observed in seven
studies [5, 17, 38, 47, 49–51]. Women used more herbal
supplements than men [5, 49], while a significantly higher
prevalence of use of five or more prescription medications
among women aged 57 through 64 years was reported in
two studies [5, 17]. Consequently, more women than men
concurrently use HMPs with prescription medicines
[5, 38, 50, 51]. Qato et al. [5] found up to 60% of women in
the oldest age groups used prescription medications in
combination with herbal dietary supplements. Furthermore,
increased odds for a co-user to be female (34 vs. 18%,
p = 0.001) and older (more than one in every three were
older than 50 years of age) was also confirmed by Djuv
et al. [51].
Two studies [45, 50] found no association between age
and concurrent use. Singh and Levine [47] reported that
older users who combined prescriptions with NHPs, and
females, were more likely to have potential interactions
than males who combined prescriptions with NHPs (63 vs.
48%).
3.3.3.3 Disease State or Clinical Condition Five studies
[47, 50–53] compared concurrent use with disease state or
clinical conditions. Herbal product use was slightly higher
among participants who experienced ongoing health
problems (31.1%) than healthy older adults (24.9%),
although the difference was not significant. Consequently,
herbal product use was significantly higher among partic-
ipants who reported continuous drug use compared with
those who did not use any drugs [52]. Increased levels of
co-use were associated with the use of analgesics or a
dermatological drug [51], and chronic diseases were asso-
ciated with an increased likelihood of concurrent pre-
scription and supplement use [50]. High blood pressure and
diabetes were also strongly associated with potential
interaction [47]. However, Delgoda et al. [53] found no
significant association between concurrent herb–drug use
and a participant’s disease.
3.3.3.4 Education and Household Income Only four
studies [47, 50, 52, 53] assessed the educational level or
household income of participants with concurrent use.
Concurrent herb–drug use was greater among individuals
who had an education no higher than secondary level
[50, 53], and higher education was associated with a lower
probability of potential interaction [47]. Therefore, com-
pared with post-secondary graduates, participants with less
than a high-school education were 70% more likely to
exhibit at least one potential interaction [47].
The prevalence of concurrent herb–drug use was also
greater among individuals from households with a lower
household income or with no form of health insurance [53].
Having private medical insurance was associated with an
increased likelihood of using HMPs [50]; however, Turk-
menoglu et al. [52] found no significant associations
between HMP use and income.
3.3.3.5 Disclosure of HMP Use to Healthcare Profes-
sionals Only six of the included studies asked partici-
pants if the use of HMPs was disclosed to their doctors or
other healthcare professionals [41, 44, 45, 51–53]. No
distinct trend was observed among the six studies and
disclosure varied widely between 12% [52] and 78% [44].
A study of 1418 older adults [52] reported that 42.2%
(n = 180) of concurrent users believed herbal products
were not harmful and therefore did not need to discuss
these with their healthcare providers. Although 51 partic-
ipants (12%) always reported herbal use to their physician,
40% (n = 169) would only disclose herbal product use to
healthcare providers if asked, and 2.8% (n = 12) would
only disclose herbal product use if they had a problem. In
another study [44], 78% of participants reported HMP use,
although 58 of the 99 concurrent users said they were not
questioned by healthcare practitioners on their HMP use.
Approximately 64% of co-users (n = 18) of HMPs and
prescription drugs disclosed use in one study [41], while in
another study, almost 80% of users of HMPs did not dis-
close use [51].
3.3.3.6 Expenditure on HMPs and Satisfaction Only two
studies conducted in the US in 2002 and 2004 [41, 44],
respectively, considered the cost or resources spent on
HMPs by older adults. The majority of concurrent users (64
and 83%) spent $25 or less on HMPs per month, approx-
imately 15% spent between $25 and $50 per month [44],
and only 3 of 28 (11%) [41] and 1 of 99 (1%) [44] con-
current users spent more than $100 per month on HMPs.
3.4 Quality Appraisal
Considering the paucity of research in this area, a cut-off
score of 4 was accepted for each JBI checklist to ensure
there were sufficient studies to review while maintaining
the strength of methodological quality. Typically, research
in this area is not randomised; a score of 7 and above
indicated high quality, while a score of 4–6 indicated
moderate quality. All 22 studies were of sufficient quality
and were included in this review.
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4 Discussion
This systematic review included a total of 22 studies that
investigated concurrent use of prescription medicines with
HMPs. The majority of studies were conducted in the US,
with only four of the studies being conducted in the last
5 years. It can be concluded from the results presented that
the prevalence of concurrent prescription and HMP use
among older adults is substantial. The most commonly
combined prescription drugs by older adults are antihy-
pertensive drugs, b-blockers, diuretics, antihyperlipidemic
agents, anticoagulants, analgesics, antihistamines, antidia-
betics, antidepressants and statins. And the HMPs most
commonly combined include Ginkgo biloba, garlic, gin-
seng, St John’s wort, Echinacea, saw palmetto, evening
primrose and ginger. Furthermore, there are demographic
and clinical factors associated with concurrent prescription
and HMP use. Women, as well as individuals in the oldest
age groups, with chronic conditions, less than a high-school
education and receiving a low income, are more likely to
be concurrent users. The most common potential interac-
tion was the risk of bleeding from combinations of Ginkgo
biloba, garlic or ginseng with aspirin and warfarin, all of
which are frequently used by older adults.
The included studies varied greatly in terms of partici-
pants, products and outcome measures. Generic terms such
as ‘elderly’ or ‘older persons’ are commonly used [57], but
there is no concrete definition of these terms. While ageing
is an inevitable process measured by chronological age, its
impact varies across populations [58]; therefore, different
definitions and chronological age are adopted in clinical
studies. While some authors regarded ‘older adults’ or
‘elderly’ as those aged 65 years and older, others used the
cut-off point of 60 years, or even 75 years, which affected
both how participants were grouped and the synthesis of
data. Furthermore, many studies looked at adult popula-
tions including ‘older adults’ or ‘elderly’, but did not, or
only partially, report results separately for this age group.
In the latter case, only results that were clearly reported for
adults aged 65 years and older were included in our anal-
ysis. We therefore had to exclude a number of potentially
relevant articles due to either a lack of definition or sepa-
rate reporting.
The heterogeneity in definitions adopted for HMPs and
the inconsistencies on what is included as an HMP
demonstrates the lack of precision around what may or may
not be seen as an HMP. While one study [54] adopted the
term ‘complementary and alternative medicine’, excluding
vitamins and minerals, other studies adopted the terms
‘natural health product’ and ‘dietary supplements’,
including both vitamins and minerals. Moreover, many did
not differentiate between HMPs and dietary supplements,
but rather included all types of medications, including
vitamins, minerals, and herbal and non-herbal dietary
supplements. We only included studies of HMPs that were
explicitly named in the Results section. This variation did
not allow for comparisons across studies to be conducted,
and also blurred what might be seen as nutritional inter-
ventions to improve overall health and those that are used
explicitly for medicinal purposes to address specific med-
ical conditions.
The prevalence of concurrent prescriptions and HMP
use among adults aged 65 years and older ranged from 5.3
to 88.3%. Several factors might explain the discrepancies
in the prevalence of concurrent use reported in studies
included in this review. First, variation in the range of
prevalence reflected the different definitions, types of
HMPs assessed, and participants. Second, many of the
studies relied on patient recall of the prescription and
herbal medicines they use, possibly resulting in recall bias.
In some studies [5, 17, 42, 48, 50, 54], participants took
bottles and containers of medicines they were taking along
to interviews, for documentation by the research teams.
One of the outliers, an analysis of the 2000–2001
Canadian National Population Health Survey, reported
only 5.3% concurrent use of NHPs with prescription
medications [47]. This difference in prevalence may be
explained by underreporting or recall bias due to how the
data were collected. Participants were asked for the med-
ications and NHPs used in the previous 24 h. This is
unusual compared with other surveys on this topic where
current and previous use over 2 weeks [42] and up to
12 months was requested [38, 41, 49]. Therefore, the data
may have revealed only a percentage of respondents
exposed to an NHP during a limited time period. In addi-
tion, herbs and other NHPs are widely used in a variety of
foods, beverages, and multivitamin supplements, but
because these were not specifically asked about in the
survey, it is possible that their use was not reported.
Therefore, the true prevalence of concurrent prescription–
NHP interactions in the study population may be higher
than reported.
The other outlier is a Spanish study that reported a
prevalence of concurrent use of 88.3%. The study assessed
both commercially prepared HMPs and home remedies
concurrently used with prescription medicines among
community-dwelling older adults and those resident in care
homes. All medicinal plants, including teas and spices,
widely consumed in Spain were included in the analysis,
which may have contributed to the high prevalence rate
recorded in this study.
Three [5, 42, 45] of the five studies [5, 36, 42, 45, 52]
with the highest prevalence rates, ranging between 45.3
and 83%, were conducted in the US. These high prevalence
rates could be due to the healthcare system or the
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sociocultural characteristics of the location where research
was conducted. For the American studies, patients poten-
tially used HMPs and non-prescription drugs for prevention
or self-treatment [45] as alternatives to expensive medical
consultations and prescription drugs. Second, only one [42]
of the five studies provided a definition of what is regarded
as an HMP. Considering the inconsistencies in what HMPs
include, it is possible that other non-herbal dietary products
were considered.
Demographic characteristics, as well as health status,
have been associated with the use of herbal medicines and
natural products. Sex, age, ethnicity and health status may
result in greater use of herbs and natural products [38].
Although only 50% of the studies included in this review
compared demographic characteristics and health status
with concurrent use, the results confirm earlier findings
[11] that the use of herbal medicines varies widely between
countries and ethnic groups. For example, the two Cana-
dian studies [47, 48] reported lower rates compared with
studies from the US. In addition, the rate of combining
prescription medications and dietary supplements was
higher among women than men across all age groups
[5, 17]. These trends were also reported in earlier studies
[59, 60].
Sex differences in concurrent use among older adults
may be explained by the higher prevalence of chronic
conditions among women compared with men [61]. Con-
current use was greater among older adults from house-
holds with a lower household income, no health insurance
and no post-secondary education, which may be due to the
type of healthcare system, i.e. paid for or free at the point
of delivery. It is therefore reasonable to assume that in such
countries, participants may rely more on HMPs, or use
them as alternatives to expensive medical consultations.
Although there is increased awareness of interactions
between conventional drugs and HMPs, the lack of
agreement about how to identify HMPs or rigorous clinical
evidence hinders researchers, clinicians and consumers in
making informed decisions about safe combinations of
conventional drugs and HMPs [62]. The majority of the
evidence on herb–drug interactions is from case reports.
Arguably, the scarcity and poor quality of primary research
may mean that interactions of serious consequences asso-
ciated with concurrent use of HMPs are unknown and
unrecognised [63]. The evidence from this review would
suggest that there is potential for harm.
There is a potentially high rate of unreported use of
HMPs among older adults. Only 28% of included studies
asked participants if the use of HMPs was disclosed to
healthcare professionals. Our findings confirm previous
research [64–66] that only approximately one-third of
HMP users disclose use to healthcare professionals. Dis-
closure of herbal medicine use is crucial to avoiding herb–
drug interactions and non-adherence to prescription medi-
cations. The reasons for non-disclosure of HMP use, as
reported in this review and confirmed by other studies,
includes a perceived negative attitude of clinicians to
complementary medicine use [66, 67], clinicians do not ask
[66, 68, 69], and the notion that HMPs are ‘harmless’ [68].
4.1 Limitations
The main limitation of this review is the heterogeneity or
non-definition of HMPs in available studies, which pre-
vented a meta-analysis. Second, we had to exclude a large
number of studies because either the use of HMPs was
unclear or results reported were not age-specific to enable
us to extract data for subjects agedC 65 years. Finally,
only four of the included studies were published in the last
5 years [36, 50–52]; 17 were published between 2000 and
2010, and one case report was published in 1999 [39]. The
increasing use of HMPs worldwide could mean that the
review underestimates the range and scale of the issues.
4.2 Implications for Practice
Evidence from this review indicates that a large number of
older adults concurrently use prescription drugs and HMPs,
and the majority do not disclose this to healthcare practi-
tioners. However, the findings do demonstrate that certain
combinations of prescription drugs and HMPs can have
serious consequences. Therefore a better understanding of
the extent and manner in which older adults combine
prescription drugs and HMPs in their health regimens, and
the associated risks, is important for healthcare
practitioners.
5 Conclusions
The prevalence of concurrent use of prescription drugs and
HMPs by older adults is generally substantial, although
variations in the extent of use are reported. These varia-
tions can be explained by methodological factors, including
definition of HMPs, participant selection, sociodemo-
graphic factors and differences in healthcare systems.
Concurrent use of prescription drugs and HMPs is associ-
ated with risks, some with potentially serious conse-
quences. The most reported interactions in older adults
were risk of bleeding due to the use of Ginkgo biloba,
garlic or ginseng in combination with aspirin and warfarin
or other antithrombotic drugs. Underreporting is substantial
and adds to the problem, considering that in most countries
there are no appropriate safeguards to minimise the
potential harm. By identifying the most commonly used
combinations, healthcare professionals, including
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pharmacists, can be informed on how to appropriately
identify and manage patients at risk. It also highlights the
need for targeted patient information provided by health-
care professionals and pharmacists as part of routine con-
sultations. Further research is needed to explore why older
people use HMPs alongside their prescribed medication,
and how their decisions regarding preferred treatments can
be documented and discussed by prescribing clinicians, in
order to identify and manage the potential risk of herb–
drug interactions.
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